Cargando…
Progress in the Application of Drugs for the Treatment of Multiple Sclerosis
Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis o...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313804/ https://www.ncbi.nlm.nih.gov/pubmed/34326775 http://dx.doi.org/10.3389/fphar.2021.724718 |
_version_ | 1783729418444734464 |
---|---|
author | Wei, Weipeng Ma, Denglei Li, Lin Zhang, Lan |
author_facet | Wei, Weipeng Ma, Denglei Li, Lin Zhang, Lan |
author_sort | Wei, Weipeng |
collection | PubMed |
description | Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis of MS, its etiology still remains unclear. At present, there is no complete cure, but there are drugs that decelerate the progression of MS. Traditional therapies are disease-modifying drugs that control disease severity. MS drugs that are currently marketed mainly aim at the immune system; however, increasing attention is being paid to the development of new treatment strategies targeting the CNS. Further, the number of neuroprotective drugs is presently undergoing clinical trials and may prove useful for the improvement of neuronal function and survival. In this review, we have summarized the recent application of drugs used in MS treatment, mainly introducing new drugs with immunomodulatory, neuroprotective, or regenerative properties and their possible treatment strategies for MS. Additionally, we have presented Food and Drug Administration-approved MS treatment drugs and their administration methods, mechanisms of action, safety, and effectiveness, thereby evaluating their treatment efficacy. |
format | Online Article Text |
id | pubmed-8313804 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83138042021-07-28 Progress in the Application of Drugs for the Treatment of Multiple Sclerosis Wei, Weipeng Ma, Denglei Li, Lin Zhang, Lan Front Pharmacol Pharmacology Multiple sclerosis (MS) is an autoimmune and chronic inflammatory demyelinating disease of the central nervous system (CNS), which gives rise to focal lesion in CNS and cause physical disorders. Although environmental factors and susceptibility genes are reported to play a role in the pathogenesis of MS, its etiology still remains unclear. At present, there is no complete cure, but there are drugs that decelerate the progression of MS. Traditional therapies are disease-modifying drugs that control disease severity. MS drugs that are currently marketed mainly aim at the immune system; however, increasing attention is being paid to the development of new treatment strategies targeting the CNS. Further, the number of neuroprotective drugs is presently undergoing clinical trials and may prove useful for the improvement of neuronal function and survival. In this review, we have summarized the recent application of drugs used in MS treatment, mainly introducing new drugs with immunomodulatory, neuroprotective, or regenerative properties and their possible treatment strategies for MS. Additionally, we have presented Food and Drug Administration-approved MS treatment drugs and their administration methods, mechanisms of action, safety, and effectiveness, thereby evaluating their treatment efficacy. Frontiers Media S.A. 2021-07-13 /pmc/articles/PMC8313804/ /pubmed/34326775 http://dx.doi.org/10.3389/fphar.2021.724718 Text en Copyright © 2021 Wei, Ma, Li and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Wei, Weipeng Ma, Denglei Li, Lin Zhang, Lan Progress in the Application of Drugs for the Treatment of Multiple Sclerosis |
title | Progress in the Application of Drugs for the Treatment of Multiple Sclerosis |
title_full | Progress in the Application of Drugs for the Treatment of Multiple Sclerosis |
title_fullStr | Progress in the Application of Drugs for the Treatment of Multiple Sclerosis |
title_full_unstemmed | Progress in the Application of Drugs for the Treatment of Multiple Sclerosis |
title_short | Progress in the Application of Drugs for the Treatment of Multiple Sclerosis |
title_sort | progress in the application of drugs for the treatment of multiple sclerosis |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8313804/ https://www.ncbi.nlm.nih.gov/pubmed/34326775 http://dx.doi.org/10.3389/fphar.2021.724718 |
work_keys_str_mv | AT weiweipeng progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis AT madenglei progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis AT lilin progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis AT zhanglan progressintheapplicationofdrugsforthetreatmentofmultiplesclerosis |